These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 38772713)

  • 21. Low-frequency enzyme replacement therapy in late-onset Pompe disease.
    Lin DS; Chiang MF; Ho CS; Hsiao CD; Lin CY; Wang NL; Chuang CK; Huang YW; Chang PC; Liu HL
    Muscle Nerve; 2013 Apr; 47(4):612-3. PubMed ID: 23322609
    [No Abstract]   [Full Text] [Related]  

  • 22. Long-term enzyme-replacement therapy (ERT) with alglucosidase alfa: Evolution of two siblings with juvenile late-onset Pompe disease.
    Rafael Bretón Martínez J; Martínez AC
    J Neurol Sci; 2015 Nov; 358(1-2):459-60. PubMed ID: 26279333
    [No Abstract]   [Full Text] [Related]  

  • 23. Imino sugar therapy for type 1 Gaucher disease.
    Priestman DA; Platt FM; Dwek RA; Butters TD
    Glycobiology; 2000 Nov; 10(11):iv-vi. PubMed ID: 11221677
    [No Abstract]   [Full Text] [Related]  

  • 24. Long-term safety and efficacy of cipaglucosidase alfa plus miglustat in individuals living with Pompe disease: an open-label phase I/II study (ATB200-02).
    Byrne BJ; Schoser B; Kishnani PS; Bratkovic D; Clemens PR; Goker-Alpan O; Ming X; Roberts M; Vorgerd M; Sivakumar K; van der Ploeg AT; Goldman M; Wright J; Holdbrook F; Jain V; Benjamin ER; Johnson F; Das SS; Wasfi Y; Mozaffar T
    J Neurol; 2024 Apr; 271(4):1787-1801. PubMed ID: 38057636
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Successful switch from enzyme replacement therapy to miglustat in an adult patient with type 1 Gaucher disease: a case report.
    Giuffrida G; Lombardo R; Di Francesco E; Parrinello L; Di Raimondo F; Fiumara A
    J Med Case Rep; 2016 Nov; 10(1):315. PubMed ID: 27821156
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Unwarranted, long term, alglucosidase alfa enzyme replacement therapy in two non-Pompe disease patients.
    Karam C; Ragole T; Moshe-Lilie O; Chahin N
    Clin Neurol Neurosurg; 2020 Sep; 196():106048. PubMed ID: 32623214
    [No Abstract]   [Full Text] [Related]  

  • 27. Ptosis in Pompe disease: common genetic background in infantile and adult series.
    Ravaglia S; Bini P; Garaghani KS; Danesino C
    J Neuroophthalmol; 2010 Dec; 30(4):389-90. PubMed ID: 21107130
    [No Abstract]   [Full Text] [Related]  

  • 28. 5-
    Kato A; Nakagome I; Kanekiyo U; Lu TT; Li YX; Yoshimura K; Kishida M; Shinzawa K; Yoshida T; Tanaka N; Jia YM; Nash RJ; Fleet GWJ; Yu CY
    J Med Chem; 2022 Feb; 65(3):2329-2341. PubMed ID: 35072486
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A bacterial glycosidase enables mannose-6-phosphate modification and improved cellular uptake of yeast-produced recombinant human lysosomal enzymes.
    Tiels P; Baranova E; Piens K; De Visscher C; Pynaert G; Nerinckx W; Stout J; Fudalej F; Hulpiau P; Tännler S; Geysens S; Van Hecke A; Valevska A; Vervecken W; Remaut H; Callewaert N
    Nat Biotechnol; 2012 Dec; 30(12):1225-31. PubMed ID: 23159880
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Enhanced efficacy of enzyme replacement therapy in Pompe disease through mannose-6-phosphate receptor expression in skeletal muscle.
    Koeberl DD; Luo X; Sun B; McVie-Wylie A; Dai J; Li S; Banugaria SG; Chen YT; Bali DS
    Mol Genet Metab; 2011 Jun; 103(2):107-12. PubMed ID: 21397538
    [TBL] [Abstract][Full Text] [Related]  

  • 31. When should we start enzyme replacement therapy for infantile Pompe disease with severe cardiomyopathy?
    Bonilla-Palomas JL; Gámez-López AL; Tejero-Hernández MA; Tejero-Mateo I; López-López J
    Rev Esp Cardiol (Engl Ed); 2012 Jan; 65(1):100-2. PubMed ID: 21715078
    [No Abstract]   [Full Text] [Related]  

  • 32. Improvement of bilateral ptosis on higher dose enzyme replacement therapy in Pompe disease.
    Yanovitch TL; Casey R; Banugaria SG; Kishnani PS
    J Neuroophthalmol; 2010 Jun; 30(2):165-6. PubMed ID: 20404746
    [No Abstract]   [Full Text] [Related]  

  • 33. Four unreported types of glycans containing mannose-6-phosphate are heterogeneously attached at three sites (including newly found Asn 233) to recombinant human acid alpha-glucosidase that is the only approved treatment for Pompe disease.
    Park H; Kim J; Lee YK; Kim W; You SK; Do J; Jang Y; Oh DB; Il Kim J; Kim HH
    Biochem Biophys Res Commun; 2018 Jan; 495(4):2418-2424. PubMed ID: 29274340
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Salmeterol enhances the cardiac response to gene therapy in Pompe disease.
    Han SO; Li S; Koeberl DD
    Mol Genet Metab; 2016 May; 118(1):35-40. PubMed ID: 27017193
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Avalglucosidase alfa: First Approval.
    Dhillon S
    Drugs; 2021 Oct; 81(15):1803-1809. PubMed ID: 34591286
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of antihypertensive drugs in combination with enzyme replacement therapy in mice with Pompe disease.
    Han SO; Haynes AC; Li S; Abraham DM; Kishnani PS; Steet R; Koeberl DD
    Mol Genet Metab; 2020 Feb; 129(2):73-79. PubMed ID: 31645300
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Adjunctive albuterol enhances the response to enzyme replacement therapy in late-onset Pompe disease.
    Koeberl DD; Austin S; Case LE; Smith EC; Buckley AF; Young SP; Bali D; Kishnani PS
    FASEB J; 2014 May; 28(5):2171-6. PubMed ID: 24443373
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A beta-blocker, propranolol, decreases the efficacy from enzyme replacement therapy in Pompe disease.
    Han SO; Pope R; Li S; Kishnani PS; Steet R; Koeberl DD
    Mol Genet Metab; 2016 Feb; 117(2):114-9. PubMed ID: 26454691
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Carbohydrate-remodelled acid alpha-glucosidase with higher affinity for the cation-independent mannose 6-phosphate receptor demonstrates improved delivery to muscles of Pompe mice.
    Zhu Y; Li X; McVie-Wylie A; Jiang C; Thurberg BL; Raben N; Mattaliano RJ; Cheng SH
    Biochem J; 2005 Aug; 389(Pt 3):619-28. PubMed ID: 15839836
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Enzyme replacement therapy for infantile-onset Pompe disease.
    Chen M; Zhang L; Quan S
    Cochrane Database Syst Rev; 2017 Nov; 11(11):CD011539. PubMed ID: 29155436
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.